文献速递流行病学与生物统计

成人潜伏性结核感染筛查:美国预防服务工作组更新证据报告与系统综述

Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2023-01-01

本系统综述纳入112项研究(N=69 009),未发现直接评估潜伏性结核感染(LTBI)筛查获益与危害的研究。结核菌素皮肤试验(TST)和干扰素-γ释放试验(IGRAs)具有中等敏感度和高特异度;推荐方案治疗LTBI可降低进展为活动性结核的风险,异烟肼肝毒性高于安慰剂或利福平。

要点

  • 无研究直接评估LTBI筛查的获益与危害。
  • TST在5mm阈值敏感度0.80,IGRAs敏感度0.81-0.90,特异度0.95-0.99。
  • 异烟肼24周较安慰剂降低5年活动性结核风险(RR 0.35),但肝毒性增加(RR 4.59)。

核心结论

  • 无研究直接评估LTBI筛查与不筛查相比的获益与危害。
  • TST和IGRAs具有中等敏感度和高特异度。
  • 推荐方案治疗LTBI可降低进展为活动性结核的风险。
  • 异烟肼肝毒性发生率高于安慰剂或利福平。

研究设计与样本

  • 系统综述纳入113篇出版物(112项研究;N=69 009),检索PubMed/MEDLINE、Cochrane图书馆和试验注册库至2021年12月3日,文献监测至2023年1月20日。
  • 纳入英文的LTBI筛查、LTBI治疗或TST/IGRAs准确性研究;排除公共卫生监测或疾病管理的LTBI筛查和治疗研究。
  • 双人审查摘要、全文和研究质量;定性综合;相似研究足够时进行Meta分析。

主要发现

  • TST敏感度汇总估计:5mm硬结阈值0.80(95%CI 0.74-0.87),10mm阈值0.81(95%CI 0.76-0.87),15mm阈值0.60(95%CI 0.46-0.74)。
  • IGRAs敏感度汇总估计范围为0.81(95%CI 0.79-0.84)至0.90(95%CI 0.87-0.92)。
  • 筛查试验特异度汇总估计范围为0.95至0.99。
  • 一项大型(n=27 830)高质量随机临床试验:异烟肼24周较安慰剂5年进展为活动性结核的RR为0.35(95%CI 0.24-0.52),需治疗人数112;肝毒性增加(RR 4.59 [95%CI 2.03-10.39];需伤害人数279)。
  • Meta分析:异烟肼较利福平肝毒性风险更高(汇总RR 4.22 [95%CI 2.21-8.06];n=7339)。

关键数值与推荐

  • TST敏感度:5mm阈值0.80(95%CI 0.74-0.87);10mm阈值0.81(95%CI 0.76-0.87);15mm阈值0.60(95%CI 0.46-0.74)。
  • IGRAs敏感度范围0.81(95%CI 0.79-0.84)至0.90(95%CI 0.87-0.92)。
  • 筛查试验特异度范围0.95至0.99。
  • 异烟肼24周较安慰剂:5年活动性结核RR 0.35(95%CI 0.24-0.52),需治疗人数112;肝毒性RR 4.59(95%CI 2.03-10.39),需伤害人数279。
  • 异烟肼较利福平肝毒性汇总RR 4.22(95%CI 2.21-8.06;n=7339)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无研究直接评估LTBI筛查与不筛查相比的获益与危害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Latent tuberculosis infection (LTBI) can progress to active tuberculosis disease, causing morbidity and mortality. OBJECTIVE: To review the evidence on benefits and harms of screening for and treatment of LTBI in adults to inform the US Preventive Services Task Force (USPSTF). DATA SOURCES: PubMed/MEDLINE, Cochrane Library, and trial registries through December 3, 2021; references; experts; literature surveillance through January 20, 2023. STUDY SELECTION: English-language studies of LTBI screening, LTBI treatment, or accuracy of the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). Studies of LTBI screening and treatment for public health surveillance or disease management were excluded. DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings; meta-analyses conducted when a sufficient number of similar studies were available. MAIN OUTCOMES AND MEASURES: Screening test accuracy; development of active tuberculosis disease, transmission, quality of life, mortality, and harms. RESULTS: A total of 113 publications were included (112 studies; N = 69 009). No studies directly evaluated the benefits and harms of screening. Pooled estimates for sensitivity of the TST were 0.80 (95% CI, 0.74-0.87) at the 5-mm induration threshold, 0.81 (95% CI, 0.76-0.87) at the 10-mm threshold, and 0.60 (95% CI, 0.46-0.74) at the 15-mm threshold. Pooled estimates for sensitivity of IGRA tests ranged from 0.81 (95% CI, 0.79-0.84) to 0.90 (95% CI, 0.87-0.92). Pooled estimates for specificity of screening tests ranged from 0.95 to 0.99. For treatment of LTBI, a large (n = 27 830), good-quality randomized clinical trial found a relative risk (RR) for progression to active tuberculosis at 5 years of 0.35 (95% CI, 0.24-0.52) for 24 weeks of isoniazid compared with placebo (number needed to treat, 112) and an increase in hepatotoxicity (RR, 4.59 [95% CI, 2.03-10.39]; number needed to harm, 279). A previously published meta-analysis reported that multiple regimens were efficacious compared with placebo or no treatment. Meta-analysis found greater risk for hepatotoxicity with isoniazid than with rifampin (pooled RR, 4.22 [95% CI, 2.21-8.06]; n = 7339). CONCLUSIONS AND RELEVANCE: No studies directly evaluated the benefits and harms of screening for LTBI compared with no screening. TST and IGRAs were moderately sensitive and highly specific. Treatment of LTBI with recommended regimens reduced the risk of progression to active tuberculosis. Isoniazid was associated with higher rates of hepatotoxicity than placebo or rifampin.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Jonas DE, Riley SR, Lee LC, et al. Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023. PMID: 37129650. doi:10.1001/jama.2023.3954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。